Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Erdheim-Chester disease (ECD), also known as non-Langerhans cell histiocytosis, is a multi-systemic disease with unclear pathogenesis. Based on a small number of case studies, pegylated interferon-α (PEG-IFN-α) has been used as the front-line treatment option. However, there are limited data regarding administration of ropegylated-interferon α-2b (ROPEG-IFN-α 2b) for ECD patients. Herein, we report two cases of severe ECD treated with two types of PEG-IFN-α. One patient with heart and skeleton involvement and BRAF V600E mutation was treated with weekly PEG-IFN-α 2a. Another patient with bone involvement and no BRAF V600E mutation was administered monthly ROPEG-IFN-α 2b. The two types of PEG-IFN-α showed excellent disease control, excellent survival outcomes, and manageable toxicities in ECD patients. These results suggest that ROPEG-IFN-α 2b could be used equivalently to PEG-IFN-α 2a for management of advanced ECD.
Abstract
Erdheim-Chester disease (ECD), also known as non-Langerhans cell histiocytosis, is a multi-systemic disease with unclear pathogenesis. Based on a small number of case studies, pegylated interferon-α (PEG-IFN-α) has been used as the front-line treatment option. However, there are limited data regarding administration of ropegylated-interferon α-2b (ROPEG-IFN-α 2b) for ECD patients. Herein, we report two cases of severe ECD treated with two types of PEG-IFN-α. One patient with heart and skeleton involvement and BRAF V600E mutation was treated with weekly PEG-IFN-α 2a. Another patient with bone involvement and no BRAF V600E mutation was administered monthly ROPEG-IFN-α 2b. The two types of PEG-IFN-α showed excellent disease control, excellent survival outcomes, and manageable toxicities in ECD patients. These results suggest that ROPEG-IFN-α 2b could be used equivalently to PEG-IFN-α 2a for management of advanced ECD.
참고문헌 (15)
- Arnaud L, "CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease : a multicenter survival analysis of 53 patients", Blood, 117, pp.2778~2782 (2011)
- Munoz J, "Erdheim-Chester disease : characteristics and management", Mayo Clin Proc, 89, pp.985~996 (2014)
- Vassallo R, "Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults", N Engl J Med, 346, pp.484~490 (2002)
- Haroche J, "High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses", Blood, 120, pp.2700~2703 (2012)
- Diamond EL, "Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease", Blood, 124, pp.483~492 (2014)
- Arnaud L, "Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease : a single-center series of 37 patients", Blood, 117, pp.2783~2790 (2011)
- Dagna L, "Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease : rationale for the treatment of patients with infliximab", J Clin Oncol, 30, pp.e286~90 (2012)
- Stoppacciaro A, "Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease : implications for pathogenesis", Arthritis Rheum, 54, pp.4018~4022 (2006)
- Mossetti G, "Biochemical markers of bone turnover, serum levels of interleukin-6", interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease, 2003, pp.21, 232~236
- Braiteh F, "Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha", Blood, 106, pp.2992~2994 (2005)
- Gisslinger H, "Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera(PROUD-PV and CONTINUATION-PV) : a randomised, non-inferiority, phase 3 trial and its extension study", Lancet Haematol, 7, pp.e196~208 (2020)
- Haroche J, "Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement : results in eight patients", Arthritis Rheum, 54, pp.3330~3336 (2006)
- Hervier B, "Treatment of Erdheim-Chester disease with long-term high-dose interferon-alpha", Semin Arthritis Rheum, 41, pp.907~913 (2012)
- Goyal G, "Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease", JAMA Oncol, 3, pp.1253~1256 (2017)
- Mazor RD, "Erdheim-Chester Disease : a comprehensive review of the literature", Orph-anet J Rare Dis, 8, pp.137~ (2013)